ROMA (ITALPRESS) – In an international scenario characterized by geopolitical instability, macroeconomic pressures, increasing demand and difficulty of access to health, Italy is called to define an industrial and scientific policy capable of strengthening its competitiveness in Life Sciences. The event “Guideing Innovation towards an Italian Strategy of Life Sciences” was held today in Rome, promoted by Sanofi, among others: University of Milan, Italy, Italy, Italy, Italy, Italy The initiative is part of a crucial moment for the sector, in which biomedical research, precision medicine, next-generation immunology and artificial intelligence are profoundly transforming care paths and productive chains. For Italy – a leading European country in pharmaceutical exports and excellence hubs for clinical research – these transformations represent a strategic opportunity to grasp through an integrated and long-term vision. “Italy has a great opportunity: to transform the vast potential of Life Sciences into a true national strategic asset – says Giovanni Tria, President of the ENEA Tech and Biomedical Foundation. The experimentation of new forms of public-private collaboration goes in this direction: enhance the scientific and clinical excellences already present in the country and integrate them with industrial, technological and productive capacity. Investing in advanced biomedical infrastructure and innovation poles allows to generate an attractive ecosystem, capable of retaining talent, attracting international investments and developing high-value chains. A strong Life Sciences sector means ability to respond more quickly to health emergencies, greater security in the supply of critical products and a more active role in European initiatives of technological sovereignty.” Approximately EUR 70 million for investment in the three key innovation levers: Research and Development, skills training and industrial technological transformation. Concrete basis of the debate, the data of the Sanofi Impact Report 2024, which offer a photograph of the value that Innovation can generate for Italy. In 2024 Sanofi invested €45.2 million in Research and Development in Italy, generating a total benefit of €133 million for the SSN and the nation in terms of cost avoided. The leverage effect is 2.95: every euro invested in research in Italy produces almost three euros of savings for the community thanks to the reduction of hospitalizations, the most appropriate use of clinical paths and the availability of innovative therapies. Moreover, the research supported by Sanofi is one of the most extensive in Italy, with 108 clinical studies conducted in the last year, which involved 1,517 patients distributed in 563 hospital and university clinical centers, thanks to the collaboration with over 90 healthcare facilities throughout the national territory. “Research is what every day allows us to transform scientific knowledge into concrete solutions for millions of people – says Marcello Cattani, President and CEO of Sanofi Italy and Malta -. Italy has a unique strength, represented by a clinical network of excellence and researchers capable of leading complex, multidisciplinary and high innovation studies. The results we observe – from the impact on the quality of life of patients to the reduction of costs for the healthcare system – show that when public research and industrial research work in synergy, innovation accelerates and becomes real value. The ambition of Sanofi is to become the leading biopharmaceutical company in immunology by 2030 investing – with over 45 million euros per year only in Italy – in increasingly advanced studies, which also thanks to a massive use of AI integrate immunology, genomics and new digital technologies. Enlargement is around 70 million euros invested in Italy by Sanofi in the three key innovation levers: Research and Development, industrial technological transformation, skills and training. In a global context of great complexity, we need to create an Italian ecosystem of Life Sciences at the height of our nation’s ambitions and a stimulus for a European industrial policy that puts the pharmaceutical sector at the centre of growth.” Besides scientific production, the research of Sanofi generates immediate health impacts. In particular, in 2024, three areas were covered in the Impact Report 2024 of a specific economic analysis: the national immunization campaign against the Syncidal Respiratory Virus in newborns, type 2 inflammatory diseases and cardiovascular diseases. The benefits for the SSN are significant, with 29,5 million euros of costs avoided thanks to the immunoprophylaxis from RSV, 20,8 million deriving from the solutions for inflammation of type 2 and 34 million related to PCSK9 inhibitors in cardiovascular prevention. It is therefore imaginable the huge impact generated by the sum of health solutions. On the front of innovation, Sanofi is also guiding a structural transformation of its pipeline, today consisting of 93 clinical projects, of which 36 are advanced or already subjected to regulatory authorities, increasingly supported by the use of artificial intelligence technologies applied to the design of studies, the management of clinical data and the generation of new therapeutic targets. And Italy plays a central role in this path: the studies conducted here include key areas such as immunology, transplants, neurology, rare diseases, diabetes, vaccines and hematology, and also include 12 innovative molecules, including some potentially “pipeline in a product” to generate over 40 new therapeutic indications by 2031. Special attention was paid to immunology, the main axis of Sanofi’s global growth and development strategy, which aims to establish a leading company in this area by 2030. In fact, 76% of the company’s studies covered solutions based on immunological action mechanisms, while investments in research on type 2 inflammatory diseases grew by 19% in only 2024. Sanofi is therefore contributing with his research and development to what Alberto Mantovani, President of the Humanitas Foundation for Research, Professor emeritus of Humanitas University has called “revolution of immunology” for years and who no longer looks at diseases as isolated categories, but at the biological paths of immunity based on many chronic and inflammatory conditions. And precisely on these issues he has intervened, deepening through his master lecture as the understanding of immune mechanisms both today at the base of the main therapeutic and prevention innovations. The event in Rome confirmed a clear message: Italy can take a leading role in Life Sciences, but this requires a shared national vision, an ecosystem that provides governance that integrates public and private research and investments capable of translating into concrete solutions for people.
– Sanofi press office photos –– News in collaboration with Sanofi –
(ITALPRESS).
